A number of molecular aberrations have been identified in non small cell lung cancer (NSCLC), including EGFR, BRAF, HER2 mutations, EML4-ALK, ROS1 and RET rearrangements in adenocarcinoma; FGFR mutations/amplifications, DDR2 or PIK3CA mutations in squamous cell carcinoma [1]. The gene discussed is ERBB2; the disease is adenocarcinoma.